🏛️ Verified NIH Record • Updated 2025-07-21
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema (NCT06007677)
A Phase 2 Long-Term Open-Label Trial to Assess the Safety and Efficacy of Repeat Dosing of STAR-0215 in Adult Patients With Hereditary Angioedema (The ALPHA-SOLAR Trial)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Astria Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Who can join: Review the eligibility criteria below.
Location: Allervie Clinical Research — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Allervie Clinical Research — Birmingham, Alabama
- Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD — Scottsdale, Arizona
- Acuro Research — Little Rock, Arkansas
- UC San Diego US HAEA Angioedema Center — San Diego, California
- Raffi Tachdjian MD, Inc — Santa Monica, California
- Allergy & Asthma Clinical Research — Walnut Creek, California
- Institute for Asthma and Allergy, PC — Chevy Chase, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Optimed Research — Columbus, Ohio
- Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania
- AARA Research Center — Dallas, Texas
- Diagnostic Consultative Center Convex Ltd. — Sofia,
- University of Alberta — Edmonton, Alberta
- Ottawa Allergy Research Corporation — Ottawa, Ontario
- Institute of Clinical Immunology/Allergology, Faculty Hospital, Hradec Kralove — Hradec Králové,
- Charité Universitätsmedizin Berlin — Berlin,
- Johann Wolfgang Goethe-Universität Frankfurt — Frankfurt,
- Universitätsklinikum Ulm — Ulm,
- Szpital Uniwersytecki w Krakowie — Krakow,
- Addenbrooke's Hospital — Cambridge,
- St. James's Hospital — Leeds,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hereditary Angioedema
- A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Birmingham, Alabama
- A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) — Paradise Valley, Arizona
- HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Scottsdale, Arizona
- Berotralstat Treatment in Children With Hereditary Angioedema — Vienna, Ontario
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) — Colorado Springs, Colorado
Explore by condition: All Hereditary Angioedema clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.